Large scale lentiviral vector production

慢病毒载体(LV)在将其基因有效载荷插入靶细胞基因组的能力方面令人惊叹。这会影响目标的永久性遗传变化，这些变化会传播到其后代。虽然有几种基因修改的方法，但很少有能够永久修改靶细胞的方法。在所有的基因传递载体中，Lvv在无与伦比的效率、安全性、无毒性和修饰未分裂的靶细胞的能力方面是独一无二的。因此，它们已被认为是蓬勃发展的细胞治疗和基因治疗行业有效发展所需的关键试剂。然而，尽管LV代表着一种广为人知的强大技术，但对于超大规模的LV生产，仍有常规制造方法。现在，无论是临床试验，还是目前开发的许多细胞和基因治疗产品的商业开发，这都是公认的瓶颈。我们建议解决这一未得到满足的需求

Lentiviral vectors (LV) are remarkable in their ability to insert their genetic payload into a target cell's genome. This affects apermanent genetic change in the target which is propagated through to its progeny. While there are several means ofgenetic modification, few are capable of permanent modification of target cells. Amongst all vectors for gene delivery, LVare unique in unparalleled efficiency, safety, lack of toxicity and ability to modify non-dividing target cells. They havetherefore come to be recognised as a key reagent required for the efficient development of the burgeoning cell therapy, aswell as gene therapy industries. However, although LV represent a well understood and robust technology, there is nomanufacturing methodology for very large-scale LV production. This is now an acknowledged bottle-neck both for clinicaltrials and for commercial exploitation of many cell and gene therapy products in current development. We propose toaddress this unmet need